Potential paths to revenue and profitability in 2025 RADNOR, Pa., July 1, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that the Company posted a new Shareholder Update Letter on its website NRx Shareholder Update and further invites interested parties to subscribe to their email alert service to stay up to date on company's progress here: NRx Email Alerts . (Note: not all updates will be included in a Press Release in the future). Today's update highlights potential paths to profitability for NRx in 2025.  Key items include: Potential 2024 Revenue from operation of HOPE Therapeutics-branded interventional psychiatry clinics Potential 2025 Revenue from sales of NRX-100 (IV Ketamine) based on an FDA New Drug Application approval Potential 2025 Revenue from sales of NRX-101 as an FDA-approved product for the sub-population of people with suicidal bipolar depression and akathisia Please see the full letter for a detailed discussion of these and other topics Please subscribe to the Company's email for future updates.  NRX Email Alerts Not all ...